Monte Rosa (GLUE) Q2 Revenue Jumps 394%

Monte Rosa Therapeutics (NASDAQ:GLUE), a biotechnology company developing molecular glue degrader therapies, announced results for the second quarter on August 7, 2025. The standout news was a sharp jump in GAAP revenue, which reached $23.2 million, well above GAAP expectations of $7.4 million. This upside was tied to continued recognition of milestone payments from key collaborations, especially with Novartis, as reflected in collaboration revenue. Net loss (GAAP) also narrowed significantly from $30.3 million in Q2 2024 to $12.3 million, while the quarter reflected robust partnership revenue and a strong cash position, giving it a long operational runway. Source: Analyst estimates for the quarter provided by FactSet. Monte Rosa Therapeutics focuses on developing molecular glue degraders, which are small molecule drugs designed to break down disease-causing proteins. These therapies aim to target proteins that were traditionally considered undruggable, hoping to improve treatment options in cancer and immune diseases. The company’s approach uses the QuEENTM Discovery Engine, an artificial intelligence and machine learning platform, to identify new drug candidates.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool